EUCTR2020-000885-40-IT进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC). - SEISMiC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Clinical presentation consistent with SCAI Stage B pre-cardiogenic shock caused by acute decompensation of chronic systolic heart failure (due to arterial hypertension, ischemic heart disease or dilated cardiomyopathy), without evidence for an acute coronary syndrome.
- •2.Signed informed consent form (ICF);
- •3.Males and females, 18 to 85 years of age (inclusive);
- •4.An admission within 36 hours prior to randomization for ADHF episode, defined as:
- •a.Dyspnea, at rest or with minimal exertion,
- •b.Congestion on chest x-ray or lung US with BNP = 400 pg/mL or NT-proBNP = 1400 pg/mL.
- •Elective admissions for medications tune up or procedures do not qualify as an ADHF admission.
- •5.History of left ventricular ejection fraction (LVEF) = 40%;
- •6.Persistent hypotension defined as
- •a.SBP between 75 and 90 mmHg for at least 2 hours prior to Screening;
- •b.SBP doesn’t decrease by > 7 mmHg on two separate measurements during the last 2 hours prior to randomization;
- •7.Heart rate 75 to 150 bpm. If the subject is on a beta-blocker, the range is 60 to 150 bpm;
- •8.Echocardiogram during index hospitalization confirming ejection fraction = 40% and no evidence of other pathology to confound interpretation of cardiac physiology (eg, pericardial effusion).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1.Cardiogenic shock of SCAI stage C or worse
- •2.Cardiogenic shock due to any other condition besides acute decompensation of chronic heart failure.
- •3.Any of the following in the past 30 days: acute coronary syndrome, coronary revascularization, MI, CABG, or percutaneous coronary intervention;
- •4.Current treatment (within 6 hours of Screening) with positive inotropic agents or vasopressors, renal support including ultrafiltration, or mechanical circulatory, ventilatory or renal support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device);
- •5.Venous Lactate > 2 mmol/L;
- •6.History of heart transplant or UNOS priority 1a heart transplant listing
- •7.Ongoing treatment with digoxin (if digoxin was stopped before signing the ICF and the digoxin plasma level is < 0.5 ng/ml, the patient may be enrolled);
- •8.Severe renal impairment (eGFR < 30 ml/min, calculated by the MDRD formula);
- •9.Hypersensitivity to the study medication and its excipients (including known lactose hypersensitivity) or any related medication;
- •10.Stroke or TIA within 3 months;
- •11.Incomplete revascularization (patients with ischemic heart disease have to have had a catheterization in the last year demonstrating that the main coronary arteries are well revascularized);
- •12.Any significant valvular disease (including moderate or severe valvular disease, such as severe aortic stenosis or regurgitation); severe tricuspid or mitral regurgitation;
- •13.Primary hypertrophic or restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease;
- •14.Admission for AHF triggered primarily by a correctable etiology such as significant arrhythmia (inclusive of atrial fibrillation as the main reason for admission), infection, severe anemia, acute coronary syndrome, pulmonary embolism, exacerbation of COPD, planned admission for device implantation, or over-diuresis as a cause of hypotension;
- •15.Pericardial constriction or active pericarditis;
- •16.Life-threatening ventricular arrhythmia or implantable cardioverter defibrillator (ICD) shock within the past month or history of sudden death within 6 months;
- •17.Cardiac resynchronization therapy (CRT), ICD, or pacemaker implantation within the past month;
- •18.Sustained ventricular tachycardia in the last 3 months with no defibrillator;
- •19.Cor pulmonale or other causes of isolated right-sided HF or not related to left ventricular dysfunction;
- •20.Acute respiratory distress syndrome;
- •21.Suspected sepsis; fever > 38° or active infection requiring IV antimicrobial treatment;
- •22.Body weight < 40 kg or = 150 kg;
- •23.Laboratory exclusions:
- •a.Hemoglobin < 9 g/dl,
- •b.Platelet count < 100,000/µl,
- •c.Serum potassium > 5.3 mmol/l or < 3.5 mmol/l;
- •24.A life expectancy < 3 months in the opinion of the investigator;
- •25.Severe pulmonary or thyroid disease;
- •26.Pregnant or breast-feeding;
- •27.Ongoing drug or alcohol abuse;
- •28.Participation in another interventional study within the past 30 days.
研究者
相似试验
进行中（未招募）
1 期
A study to test the efficacy and safety of padsevonil as treatment of focal-onset seizures in adult subjects with drug-resistant epilepsyFocal-Onset SeizuresMedDRA version: 21.1Level: LLTClassification code 10065337Term: Focal epilepsySystem Organ Class: 100000004852EUCTR2018-002303-33-BECB Biopharma SR625
招募中
3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate CancerNon-Metastatic Castration-Resistant Prostate Cancernon-spread Castration-Resistant Prostate Cancer10036958NL-OMON54510Aragon Pharmaceuticals, Inc.35
进行中（未招募）
1 期
A study to look at the effect and how safe drug VIS649 is in patients with kidney diseaseEUCTR2019-002531-29-GBVisterra, Inc.144
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, PO, BID, in Combination with Metformin in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin, Alone.Type 2 Diabetes MellitusEUCTR2009-010224-25-HUBristol-Myers Squibb International Corporation152
进行中（未招募）
不适用
Research study testing the safety and tolerability of the investigationaldrug, BMS-708163, compared to placebo (inactive substance) in subjectswith prodromal Alzheimer's DiseaseALZHEIMER DISEASEMedDRA version: 15.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2009-010067-16-SEBristol-Myers Squibb International Corporation540